Vivus Reports Results of Qsymia in Pilot Clinical Study for Patients with Laparoscopic Sleeve Gastrectomy Surgery

 Vivus Reports Results of Qsymia in Pilot Clinical Study for Patients with Laparoscopic Sleeve Gastrectomy Surgery

Vivus Reports Results of Qsymia in Pilot Clinical Study for Patients with Laparoscopic Sleeve Gastrectomy Surgery

Shots:

  • The pilot clinical study involves assessing of Qsymia (phentermine and topiramate ER caps) in 25 patients with a BMI of 50+ who were planning to undergo LSG vs patients undergoing surgery alone without anti-obesity medication (AOM)
  • The clinical study results: @24mos. BMI (33.8 kg/m2 vs 42 kg/m2); average wt. loss (28.1 kg vs 12.3 kg); @2yrs. post LSG (11.2% vs -18.2%); BMI<40 @24 post LSG (61.5% vs. 47.5%); wt. loss more than twice as much weight during preoperative treatment
  • Qsymia is an anti-obesity therapy indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults BMI of 30 kg/m2+ or 27 kg/m2+ with at least one weight-related medical condition such as high BP, T2D or high cholesterol

Click here to­ read full press release/ article | Ref: Vivus | Image: Vivus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post